Stanford researchers have developed a first-in-class, non-hormonal male contraceptive that works by targeting a protein found only in developing sperm cells.
Colorectal cancer affects 1.4 million new patients annually, with existing treatments often ineffective. A key factor in treatment resistance is high aldehyde dehydrogenase activity, which undermines several chemotherapies.